Hubei Minkang Pharma to Gain Stake in Hubei Merryclin Pharma

Hubei Minkang Pharma has signed a MoU with Hubei Merryclin Pharma to acquire a 30% to 51% interest in Merryclin. As part of the agreement, Minkang will gain immediate use of some GMP certified production facilities belonging to Merryclin that will expand its production. Minkang said the stake in Merryclin would require only a “modest” capital injection. Minkang makes TCM products along with some chemical drugs. More details.... Stock Symbol:  (OTCBB: HBMK) Share this with colleagues: // //